The invention relates to double-stranded ribonucleic acid (dsRNA) compositions targeting the ALAS1 gene, and methods of using such dsRNA compositions to alter (e.g., inhibit) expression of ALAS1.

Described herein are pet food compositions comprising—in relevant part—neutral detergent fiber and crude fiber in amounts, which are effective in inducing satiety and supporting healthy weight management. Methods of making and using these pet food compositions are also described.

The present invention relates to a novel homeopathic composition useful for treating pain and/or inflammation comprising tinctures and/or diluted extracts. More particularly, there is provided a composition which contains a synergistic combination of extracts from Terminalia arjuna, Sticta pulmonaria, Colchicum autumnale, Gelsemium sempervirens, Ledum palustre and Cissus quadrangularis. The present invention also provides a method of preparation of the homeopathic drug composition as topical preparation, preferably as topical spray composition. Cissus quadrangularis extraction is also a novel process used in the composition where in cold extraction is applied for Cissus quadrangularis.

The present invention provides compositions comprising hyaluronan with high elasticity, as well as methods for improving joint function, reducing pain associated with joint function and treating osteoarthritis by introducing into a joint a therapeutically effective amount of a composition comprising hyaluronan with high elasticity.

The present discovery generally pertains to the formulation of therapeutic compounds to treat the symptoms of esophageal disorders. More specifically, the present discovery pertains to two 1-di-alkyl-phosphinoyl-alkanes (DIPA) called DIPA-1-8 and DIPA-1-9. These compounds are formulated as a shaped medicament and swallowed to suppress the symptoms of esophageal reflux and dyspepsia. The DIPA act by creating sensations of coolness and cold on the pharyngeal and esophageal lining. Some of the symptoms relieved include cough, chronic cough, heartburn, chest pain, bloat, belching, and dyspepsia. A preferred embodiment is DIPA-1-9 dissolved in a gel matrix. An aspect of the invention is to design the medicament to be intercepted, impeded, ensnarled, or trapped in the pharyngeal valleculae and pyriform sinuses before it passes down the esophagus. The goal is to prolong the transit time of the medicament, also herein sometimes call the Shaped-Gel, in the hypopharynx and esophagus, so the active ingredient has ample time to dissolve in saliva and reach receptors for cooling. By experiment, the ideal formulation of the Shaped-Gel was a flat rectangular or toroid shape, with a mass of 0.3 to 0.8 g. Flatness was defined as a pill with the shortest axis, preferentially 5 to 45% of the longest axis.

The present discovery generally pertains to the formulation of therapeutic compounds to treat the symptoms of esophageal disorders. More specifically, the present discovery pertains to two 1-di-alkyl-phosphinoyl-alkanes (DIPA) called DIPA-1-8 and DIPA-1-9. These compounds are formulated as a shaped medicament and swallowed to suppress the symptoms of esophageal reflux and dyspepsia. The DIPA act by creating sensations of coolness and cold on the pharyngeal and esophageal lining. Some of the symptoms relieved include cough, chronic cough, heartburn, chest pain, bloat, belching, and dyspepsia. A preferred embodiment is DIPA-1-9 dissolved in a gel matrix. An aspect of the invention is to design the medicament to be intercepted, impeded, ensnarled, or trapped in the pharyngeal valleculae and pyriform sinuses before it passes down the esophagus. The goal is to prolong the transit time of the medicament, also herein sometimes call the Shaped-Gel, in the hypopharynx and esophagus, so the active ingredient has ample time to dissolve in saliva and reach receptors for cooling. By experiment, the ideal formulation of the Shaped-Gel was a flat rectangular or toroid shape, with a mass of 0.3 to 0.8 g. Flatness was defined as a pill with the shortest axis, preferentially 5 to 45% of the longest axis.

A method of administering to a patient in need thereof or contacting with a biological sample, a compound related to Formula I-e ##STR00001##
or pharmaceutically acceptable compositions thereof, is useful to inhibit activity of TLR7/8 or a mutant thereof and/or to treat a TLR7/8-mediated disorder.

Disclosed are pharmaceutical salts and co-crystals of pentoxifylline, clonidine and linsidomine with caffeic acid, protocatechuic acid or α-lipoic acid, and method for preparing thereof. Also disclosed are topical compositions comprising said salts or co-crystals and use thereof for treating pain.

Disclosed are pharmaceutical salts and co-crystals of pentoxifylline, clonidine and linsidomine with caffeic acid, protocatechuic acid or α-lipoic acid, and method for preparing thereof. Also disclosed are topical compositions comprising said salts or co-crystals and use thereof for treating pain.

Method for preventing or treating neuropathic and/or inflammatory pain, wherein said method comprises administering at least one effective dose of the phosphorothioate oligonucleotide IMT504. The preventive method may be applied to a mammal to be subjected to a medical or surgical intervention, or to a mammal that may be injured performing a risky task (for example, a soldier in a battle) to prevent development of pain after a medical intervention or injury.